Start -ups of high level inato and prenosis show a “better practice” of the AI ​​- the blog of health care

By Michael Millenson

Treating artificial intelligence as a single ingredient in a recipe for commercial success was a leading theme at the Medcity Invest 2025 conference, with this “best practice” advice of AI embodied by high-level inato and prenose start-ups.

“You have to build a business model that makes sense, then use AI,” warned Raffi Boyajian, director of Cigna Ventures and a panelist at the Medcity Invest 2025 conference in Chicago.

This feeling was taken up and underlined by his colleagues investors Aman Shah, vice-president of New Ventures at VNS Health, and Dipa Mehta, director of Valeo Ventures. The two underlined the need in an economic environment difficult to find a “burning platform” which could immediately stimulate the results of a customer.

In a separate panel, high-level inato start-ups and prenosis accentuated that AI is approaching.

Innovation customers need

Inato was appointed by Fast business Magazine as one of the most innovative companies of 2024, and the same year chosen by ferocious health care as one of its ferocious 15. The company based in Paris links drug manufacturers to patients who are difficult to install clinical trials by means of an AI-based platform which attracted more than 3,000 community research sites in more than 70 countries. By making clinical trials “more accessible, inclusive and effective”, in the company’s words, breaking a shocking model where 96% of the trials do not include a representative population, Inato has established partnerships with more than a third of the 30 main pharmaceutical companies.

By describing his technology, Inato says that he “assembled an AI agent to disidentify patients’ files, quickly determine which trials are relevant for each patient and assess patients against inclusion and exclusion criteria to assess admissibility” with precision and large -scale. However, this sentence “assembled an agent of AI” obscures a more subtle process.

Liz Beatty, co-founder of Inato and head of the strategy, described by using large “standard” languages ​​like Chatgpt and Claude, then optimize them for a particular process with algorithms adapted to each model. As new models appear, the company adapts accordingly. Although Beatty did not offer an analogy, he seemed obvious parallel to a chef choosing from the right ingredients in the right proportions to ensure the success of a recipe.

Said Beatty: “I hear:” Let’s apply the AI ​​to everything. This is not the right answer. Investors are sufficiently convinced that Inato has the right answer that they paid $ 38.2 million, according to Pitchbook.

The AI ​​was also at the heart of the success of the prenosis. The septicemia of the Immunoscore company was the first tool approved by the Food and Drug Administration using AI to predict the imminent appearance of an often fatal condition known as sepsis. Integrated into the clinical workflow, he was praised by Time The magazine as one of the “best inventions of 2024”, while Bobby Reddy Jr., co-founder of Prenosis and Chief Executive Officer, was then appointed to the Time100 health list recognizing influential individuals in global health.

Prenose based in Chicago is described as an artificial intelligence company adapting therapy to the biology of individual patients as part of “a new era of precision medicine”. As with Inato, however, the title of AI hides a more complex reality.

Septicemia is a heterogeneous syndrome with nearly 200 different symptoms possibly at stake. “The AI ​​brings it together so that we can understand the deterioration process,” said Reddy. The company used automatic learning to develop and validate a sophisticated algorithm, according to a New England Journal of Medicine study.

But the right AI was just one product ingredient. Prenose has also assembled a database of thousands of patients and set up a “wet laboratory” to find biomarkers of sepsis – and to be used for other conditions as the company widens its offers – on the basis of what is now 120,000 blood samples. The addition of biomarkers to DSE data has enabled the company to position itself as a more precise and real -time supplement to the EPIC septicemia tool provides free hospitals using its DSE.

“This is our competitive advantage,” said Reddy.

Concentrated

Just as Inato focused on AI for its specific ends, prenosis has also focused on a crucial objective. The AI ​​was used “above all to adapt to the FDA model for approval,” said Reddy.

Septicemia is caused by a hyperactive immune response to infection. It costs the American health system of billions of dollars a year, while claiming the lives of at least 350,000 people – more than all combined cancers, according to the prenose website. The World Health Organization has described sepsis a threat to global health, and the economic impact of this condition alone represents on average 2.7% of the costs of health care in a country, according to a study of 2022.

Redry by Reddy at the Invest conference was that the performance of an American hospital to prevent and effectively treat sepsis is a value -based payment factor by Medicare and in the safety score of hospital patients published by the Leapfrog group. A “burning platform”, indeed.

For prenosis and inato, the best practices of AI are based on practice. As Reddy said, AI is “just a tool” in product development.

Michael L. Millenson is president of Health Quality Advisors and a regular THCB contributor. It appeared for the first time in his column at Forbes